Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya's core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated virus (AAV) gene therapies.
Abstract highlights
Details of Tenaya's ASGCT 2025 presentations are as follows:
Tuesday, May 13, 2025
Poster Abstract Session - 6:00 pm – 7:30 pm
Wednesday, May 14, 2025
Poster Abstract Session – 5:30 pm – 7:30 pm
Following the conference, Tenaya's presentations will be available in the 'Our Science' section of the company's website.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as 'will,' 'potential,' 'may,' and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the presentation of data covering Tenaya's capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of AAV gene therapies; the therapeutic potential of Tenaya's prime editing technology in a humanized RBM20 murine model of DCM; TN-501 as a potential treatment for PLN R14del-associated DCM; the commercial potential of Tenaya's manufacturing process to support the development of more cost-effective AAV gene therapies. The forward-looking statements contained herein are based upon Tenaya's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced times; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya's continuing compliance with applicable legal and regulatory requirements; Tenaya's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya's reliance on third parties; Tenaya's manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya's ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Michelle Corral
VP, Corporate Communications and Investor Relations
Tenaya Therapeutics
[email protected]
Investors
AnneMarie Fields
Stern IR
[email protected]
Media
Wendy Ryan
Ten Bridge Communications
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Upstart (UPST) Slashes 7.7% on $500-Million Fundraising Program
We recently published . Upstart Holdings, Inc. (NASDAQ:UPST) is one of the best-performing stocks on Monday. Upstart Holdings dropped its share prices for a second day on Monday, shedding 7.71 percent to close at $63.46 apiece as investors soured on its plans to raise $500 million from the issuance of convertible senior notes. In a statement, Upstart Holdings, Inc. (NASDAQ:UPST) said that the notes will have a tenor of 7 years and will mature in 2032, unless earlier converted, repurchased, or redeemed. It also granted the initial buyers an option to purchase up to $75 million within a 13-day period beginning on the date the notes are first issued. The notes can be converted into cash or shares of its common stock, or they can prefer to convert into a combination of both. According to Upstart Holdings, Inc. (NASDAQ:UPST), proceeds from the offer will be used to pay the cost of the offering, as well as repurchase for cash a portion of its outstanding 0.25 percent Convertible Senior Notes due 2026. Photo by Clay Banks on Unsplash The balance will be allocated for general corporate purposes, which may include the repayment or retirement of existing debt, including the repurchase or retirement of the 2026 Notes. While we acknowledge the potential of UPST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
24 minutes ago
- Yahoo
Cineverse Technology Group's Flagship Brand Matchpoint™ Announces New Deals for its Proprietary Streaming Supply Chain Platform
LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Cineverse (Nasdaq: CNVS), a next-generation entertainment studio, has today announced that it has signed several new customers for Matchpoint™ — the industry-leading automated media supply chain platform that is radically changing the way video content is managed and delivered. This was announced today by Cineverse Technology Group's new EVP, Technology & General Manager of Matchpoint, Michele Edelman, who joined the Company this week in this newly-created role, following several months as a consultant. Among the new customers are a mix of studios and targeted streaming services that are using Matchpoint Dispatch – which helps launch and grow a streaming business via a fully-automated content management system, with asset ingest and delivery powered by trusted AI tools – and the scalable app building capabilities of Matchpoint Blueprint. Using both Blueprint and Dispatch are BeaconTV (true crime and paranormal), Elysium Media (positive reality and documentary) and Sweetspire TV (Where the South Tells its Stories). Additionally, producer and CEO Bob Yari's Magenta Light Studios (Bride Hard) is using Dispatch to distribute to digital platforms. Said Edelman, "Whether looking to quickly stand up a new streaming app or channel that is ready for scale, or seeking AI powered tools for content ingest and delivery, analytics and insights, or to improve their search and discovery capabilities, platforms and media companies continue to look to Matchpoint to bring solutions to problems that would otherwise take major investments of time and capital to address on their own. We are proud of the market adoption we are seeing as we continue to execute on a very robust deal pipeline that shows strong market validation, and look forward to announcing more deals in the near future." About Matchpoint™ Matchpoint™ is Cineverse's award-winning media supply chain platform that is radically changing the way content is managed and delivered. Matchpoint has replaced today's expensive, and labor-intensive video content processes with a fully transparent, automated workflow that significantly reduces costs, eliminates human error, and effortlessly facilitates content ingestion with delivery across multiple platforms and distribution models. About Cineverse Technology Group Cineverse develops proprietary technology that powers the future of entertainment, leveraging the Company's position as a pioneer in the video streaming industry along with the industry-leading strength of its development team in India. This team has dedicated years building and refining technology solutions that have pioneered streaming content management and distribution while leaning into advances in AI to set the company apart from the competition. This includes the creation of Matchpoint™, an award-winning media supply chain platform that is radically changing the way content is managed and delivered. The Company's cineSearch is an AI-powered search and discovery tool for film and television that makes deciding what to watch as entertaining as the entertainment itself. Additionally, the C360 programmatic audience network and ad-tech platform provides brands the opportunity to target and reach key fandoms wherever they are. About CineverseCineverse (Nasdaq: CNVS) is a next-generation entertainment studio that empowers creators and entertains fans with a wide breadth of content through the power of technology. It has developed a new blueprint for delivering entertainment experiences to passionate audiences and results for its partners with unprecedented efficiency, and distributes more than 71,000 premium films, series, and podcasts. Cineverse connects fans with bold, authentic, independent stories. Properties include the highest-grossing non-rated film in U.S. history; dozens of streaming fandom channels; a premier podcast network; top horror destination Bloody Disgusting; and more. Powering visionary storytelling with cutting-edge innovation, Cineverse's proprietary streaming tools and AI technology drive revenue and reach to redefine the next era of entertainment. For more information, visit CONTACTS For Media, The Lippin Group for Cineversecineverse@ For Investors, Julie Milsteadinvestorrelations@ View original content to download multimedia: SOURCE Cineverse Corp. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
AAON (AAON) Tumbles 10.49% as Earnings Disappoint
We recently published . AAON, Inc. (NASDAQ:AAON) is one of the best-performing stocks on Monday. AAON tumbled by 10.49 percent on Monday to close at $72.07 apiece following a disappointing earnings performance in the second quarter of the year. In its updated report, AAON, Inc. (NASDAQ:AAON) said net income declined by 70 percent to $15.5 million from $52 million in the same period last year. Net sales slightly dipped to $311 million from $313 million year-on-year, dragged down by an 18-percent decrease in net sales from its Oklahoma segment. In the first half of the year, net income decreased by 50.9 percent to 44.78 million from $91.2 million in the same comparable period, while net sales increased by 10 percent to $633.6 million from $575.7 million year-on-year. 'Our second quarter results fell short of our expectations and do not reflect the high standards we set for ourselves as an organization,' said AAON, Inc. (NASDAQ:AAON) CEO Matt Tobolski. Pixabay/Public Domain 'The underperformance was primarily driven by poor operational execution, mainly associated with the implementation of our new ERP system at our Longview, [Texas] facility. The April go-live of the new system directly impacted production of both finished products and coils at Longview. Since Longview supplies coils to our Tulsa, [Oklahoma] facility, this also limited Tulsa's expected production ramp. We are taking immediate and targeted actions to address these issues, strengthen execution, and ensure we are better positioned to deliver consistent results in the future,' he added. While we acknowledge the potential of AAON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
